Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Compared with the general Medicare population, patients with ESKD have worse quality metrics for end-of-life care, including a higher percentage experiencing hospitalizations and in-hospital deaths and a lower percentage referred to hospice. We developed a Concurrent Hospice and Dialysis Program in which patients may receive palliative dialysis alongside hospice services. The Program aims to improve access to quality end-of-life care and, ultimately, improve the experiences of patients, caregivers, and clinicians.

Objectives: We sought to describe () the Program and () enrollment and utilization characteristics of Program participants.

Methods: We conducted a quantitative description of demographics, patient characteristics, and utilization of Program enrollees.

Results: Of 43 total enrollees, 44% received at least one dialysis treatment, whereas 56% received no dialysis. The median (range) hospice length of stay was 9 (1-76) days for all participants and 13 (4-76) days for those who received at least one dialysis treatment. The average number of dialysis treatments was 3.5 (range 1-9) for hemodialysis and 19.2 (range 3-65) for peritoneal dialysis. Sixty-five percent of enrollees died at home, 23% in inpatient hospice, and 12% in a nursing facility; no patients died in the hospital.

Conclusions: Our 3-year experience with the Program demonstrated that enrollees had a longer median hospice stay than the previously reported 5-day median for patients with ESKD. Most patients received no further dialysis treatments despite the option to continue dialysis. Our experience provides evidence to support future work testing the effectiveness of such clinical programs to improve patient and utilization outcomes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528329PMC
http://dx.doi.org/10.1681/ASN.2022010064DOI Listing

Publication Analysis

Top Keywords

received dialysis
16
dialysis
9
patients eskd
8
end-of-life care
8
dialysis treatment
8
dialysis treatments
8
program
7
patients
6
hospice
6
description outcomes
4

Similar Publications

Super Responder of 177Lu-PSMA-617 PSMA Therapy in Patient With End-Stage Renal Disease on Hemodialysis.

Clin Nucl Med

September 2025

Department of Radiology and Nuclear Medicine, Comprehensive Cancer Care and Research Center (SQCCCRC), University Medical City, Muscat, Oman.

PSMA-targeted radioligand therapies with 177Lu-PSMA-617 have shown promising response rates with favorable toxicity in patients with metastasized castration-resistant prostate cancer. We report a case of a 72-year-old man with metastatic castration-resistant prostate cancer having comorbidities of DM, HTN, and end-stage renal disease (ESRD) on regular hemodialysis. The patient received 2 doses of 7.

View Article and Find Full Text PDF

Importance: Stoma reversal is associated with few complications. However, recent studies show that 1 in 3 patients develop an incisional hernia, for which half of the patients receive surgical correction.

Objective: To investigate whether prophylactic synthetic mesh placement in the retromuscular space during stoma reversal reduces the rate of stomal site incisional hernias.

View Article and Find Full Text PDF

Background: Patients receiving haemodialysis (HD) experience symptoms that impact quality of life. This study assessed the concordance of symptoms and symptom severity of HD patients and their perception by nurses and nephrologists.

Methods: A cross-sectional, observational study using the 30-item Dialysis Symptom Index (DSI) questionnaire was conducted in six dialysis centres in France from 1 March 2022 to 30 June 2023.

View Article and Find Full Text PDF

Anemia and iron deficiency (ID) are common and significant complications in kidney transplant recipients (KTRs) that can affect their health-related quality of life (HRQoL) and outcomes. Current anemia guidelines equate the post-transplant situation with the anemia associated with chronic kidney disease (CKD) in non-transplanted persons, not acknowledging relevant differences ranging from pathophysiology to clinical manifestation. Nephrologists caring for these patients tend to pay less attention to post-transplant anemia (PTA) and ID than in non-transplanted persons with CKD.

View Article and Find Full Text PDF

A Rare Case of Plasmablastic Myeloma After Renal Transplant.

Exp Clin Transplant

August 2025

>From the University Clinic for Nephrology, Faculty of Medicine, Saints Cyril and Methodius University in Skopje, Skopje, North Macedonia.

Posttransplant lymphoproliferative disorders are a serious complication after solid-organ transplant, with a reported incidence from 2% to 20%. Plasma cell neoplasms in solid-organ transplants represent a rare but increasingly serious complication after solid-organ transplant. We report a case of plasmablastic myeloma, a very rare variant of multiple myeloma with aggressive course and poor prognosis.

View Article and Find Full Text PDF